Early neovascular bridging of choroidal neovascularization after ranibizumab treatment.
To report three cases of early choroidal neovascularization (CNV) bridging after ranibizumab treatment. Three patients with two separated foci of CNV secondary to age-related macular degeneration (ARMD), pathologic myopia and multifocal choroiditis were treated with monthly injections of ranibizumab por a period of 3 months. All three cases showed early coalescence across the fovea of the two neovascular foci, already 1 month after the first ranibizumab injection. Best-corrected visual acuity (BCVA) decreased in the three cases more than 20 letters due to early foveal involvement. Two different foci of CNV show a great tendency to decrease patients' vision because of neovascular bridging with foveal implication.